Anna Turetsky BA, PhD

Anna is a Vice President at Lightstone Ventures (LSV), where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Boston office. Before joining Lightstone, Anna was an Analyst at Fletcher Spaght Inc., a healthcare strategy consulting firm in Boston.
Anna holds a PhD from Harvard University, which she completed under the guidance of Professor Ralph Weissleder, Director of the Center for Systems Biology at Massachusetts General Hospital. Her interdisciplinary research combined chemical biology, engineering, and translational medicine to develop novel cancer diagnostics. While at Harvard, Anna was a National Science Foundation Graduate Research Fellow, an Early Technology Assessment Fellow at the Harvard Office of Technology Development, and held leadership positions in several career development-focused student groups.